Effects of Beraprost Sodium Evaluated by Digital Infrared Thermal Imaging in Diabetic Patients with Peripheral Arterial Disease |
Park, Hyun Woo
(Department of Orthopedic Surgery, Dankook University College of Medicine)
Soh, Jae Wan (Department of Orthopedic Surgery, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine) Park, Seong Hyeon (Department of Orthopedic Surgery, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) Jeong, Jae Jung (Department of Orthopedic Surgery, Daejeon St. Mary's Hospital, College of Medicine, The Catholic University of Korea) |
1 | Diabetes fact sheet in Korea 2016 [Internet]. Seoul: Korean Diabetes Association [cited 2018 Jun 2]. Available from: http://www.diabetes.or.kr/pro/news/. |
2 | Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293:217-28. DOI |
3 | Lipsky BA, Weigelt JA, Sun X, Johannes RS, Derby KG, Tabak YP. Developing and validating a risk score for lower-extremity amputation in patients hospitalized for a diabetic foot infection. Diabetes Care. 2011;34:1695-700. DOI |
4 | Yoon HS, Choi WJ, Sung IH, Lee HS, Chung HJ, Lee JW. Effects of beraprost sodium on subjective symptoms in diabetic patients with peripheral arterial disease. Clin Orthop Surg. 2013;5:145-51. DOI |
5 | Demolis JL, Robert A, Mouren M, Funck-Brentano C, Jaillon P. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. J Cardiovasc Pharmacol. 1993;22:711-6. DOI |
6 | Lievre M, Morand S, Besse B, Fiessinger JN, Boissel JP. Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermettente (BERCI) research group. Circulation. 2000;102:426-31. DOI |
7 | Nony P, Ffrench P, Girard P, Delair S, Azoulay S, Girre JP, et al. Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects. Can J Physiol Pharmacol. 1996;74:887-93. DOI |
8 | Uchikawa T, Murakami T, Furukawa H. Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. Arzneimittelforschung. 1992;42:322-4. |
9 | Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159:2041-50. DOI |
10 | Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523-30. DOI |
11 | Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98:678-86. DOI |
12 | Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47:921-9. DOI |
13 | Belch JJ, Bell PR, Creissen D, Dormandy JA, Kester RC, McCollum RD, et al. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation. 1997;95:2298-302. DOI |
14 | Muller-Buhl U, Diehm C, Krais T, Zimmermann R, Morl H, Eckstein HH. Clinical effects of intravenous iloprost in patients with intermittent claudication. Eur J Clin Pharmocol. 1987;33:127-31. DOI |
15 | Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation. 1997;96:2782-4. DOI |
16 | Ueno Y, Koike H, Nakamura Y, Ochi Y, Annoh S, Nishio S. Effects of beraprost sodium, a prostacyclin analogue, on diabetic neuropathy in streptozotocin- induced diabetic rats. Jpn J Pharmacol. 1996;70:177-82. DOI |
17 | Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol. 1995;75:3A-10A. DOI |
18 | Goya K, Otsuki M, Xu X, Kasayama S. Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. Metabolism. 2003;52:192-8. DOI |
19 | Galie N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med. 2003;2:123-37. DOI |
20 | Aso Y, Tayama K, Takanashi K, Inukai T, Takemura Y. Changes in skin blood flow in type 2 diabetes induced by prostacyclin: association with ankle brachial index and plasma throbomodulin levels. Metabolism. 2001;50:568-72. DOI |